It has been a busy month for Australia’s leading medicinal cannabis companies with a significant amount of news flow.
Here are a few things that have caught my eye in March:
Cann Group Ltd (ASX: CAN)
Last week this medicinal cannabis company became the first of its kind to be added to a major Australian index when it was added to the All Ordinaries at the March rebalance. This could potentially bring Cann Group onto the radar of some fund managers which are restricted from buying shares outside the index.
Creso Pharma Ltd (ASX: CPH)
This morning Creso Pharma announced that it has entered into the sports and osteoarthritis market with the introduction of cannabidiol-based oral nutraceuticals and functional cosmetics addressing the need for organic and efficient relief from muscle and joint pain. According to the release, Creso has partnered with the largest independent Swiss manufacturing group FRIKE Technologies to produce the range under the cannaDOL brand.
Hydroponics Company Ltd (ASX: THC)
After the market closed on Wednesday Hydroponic Company advised that its CEO, David Radford, had resigned just a day after the resignation of its chief commercial officer, Debbie Ormsby. I find the sudden resignation of two executives to be quite worrying. Hydroponics Company’s shares are now in a trading halt.
MGC Pharmaceuticals Ltd (ASX: MXC)
Earlier this week this cannabis company announced the launch of MGC Nutraceuticals through its e-commerce platform. This new product line of cannabinoids and hemp-enhanced nutraceutical products is targeting a global nutraceutical market that was valued at approximately US$383 billion in 2016. Whilst this is a potentially very lucrative opportunity for MGC Pharmaceuticals, it is worth remembering that it is a highly competitive industry with low barriers to entry.
Zelda Therapeutics Ltd (ASX: ZLD)
At the start of the month this cannabis-focused biotech company announced that it had expanded its pancreatic cancer research collaboration agreement with Curtin University. According to the release, the expansion will focus on in vivo animal studies to investigate the effect of Zelda’s formulations in combination with existing chemotherapy agents Abraxane and Gemcitabine. Management has advised that there is growing evidence that whole plant cannabinoid extracts can impede cancer growth and potentially render the tumour more responsive to chemotherapeutic agents.
If there's one thing for sure, 2020 has been the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 30% discount from its highs. Scott believes in this stock so much, he's staked $209k of our own company money on it. Forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
As of 2.11.2020
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Northern Star (ASX:NST) and Saracen (ASX:SAR) shares on watch after merger update – November 25, 2020 4:49pm
- Is the Bravura Solutions (ASX:BVS) share price a buy? – November 25, 2020 4:36pm
- Why the Cann Group (ASX:CAN) share price is up 76% this week – November 25, 2020 3:18pm